Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Familial hypercholesterolaemia (FH) is a genetic disorder characterized by high LDL cholesterol levels.
• Standard treatments for FH include diet, simvastatin, colestyramine, and nicotinic acid.
• Patients with FH often require advanced therapeutic options to manage persistent hypercholesterolaemia.

Purpose of the Study:

• To evaluate the efficacy of atorvastatin, a novel HMG-CoA reductase inhibitor, in patients with familial hypercholesterolaemia.
• To assess the effects of atorvastatin on LDL cholesterol levels in patients with high LDLc despite standard therapy.
• To compare the effectiveness of different doses of atorvastatin against existing standard treatments.

Main Methods:

• An open-label study involving FH patients with LDLc > 5.0 mmol/L on standard therapy for at least 3 months.
• Patients received 40 mg atorvastatin daily for 6 weeks, followed by 80 mg atorvastatin daily for another 6 weeks.
• Standard therapy included diet with simvastatin (alone or with colestyramine) or nicotinic acid.

Main Results:

• Treatment with 80 mg atorvastatin resulted in a significant decrease in LDL cholesterol compared to 40 mg simvastatin alone (24% reduction) or with colestyramine (19% reduction).
• LDL cholesterol reduction with 80 mg atorvastatin was comparable to that achieved with simvastatin combined with nicotinic acid.
• Atorvastatin was well-tolerated, with no observed side-effects during the study period.

Conclusions:

• Atorvastatin is a valuable therapeutic option for patients suffering from severe hypercholesterolaemia, such as familial hypercholesterolaemia.
• The study supports the use of atorvastatin in managing high LDL cholesterol levels in challenging patient populations.
• Atorvastatin offers a promising addition to the existing treatment strategies for lipid management in FH.